1.Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD: Cholangiocarcinoma. Lancet 2005, 366(9493):1303–1314.
2.Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996, 224(4):463–473; discussion 473–465.
3.Malhi H, Gores GJ: Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006, 45(6):856–867.
4.Endo I, House MG, Klimstra DS, Gonen M, D’Angelica M, Dematteo RP, Fong Y, Blumgart LH, Jarnagin WR: Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol 2008, 15(8):2104–2112.
5.McGlynn KA, Tarone RE, El-Serag HB: A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006, 15(6):1198–1203.
6.Berdah SV, Delpero JR, Garcia S, Hardwigsen J, Le Treut YP: A western surgical experience of peripheral cholangiocarcinoma. Br J Surg 1996, 83(11):1517–1521.
7.Chu KM, Lai EC, Al-Hadeedi S, Arcilla CE, Jr., Lo CM, Liu CL, Fan ST, Wong J: Intrahepatic cholangiocarcinoma. World J Surg 1997, 21(3):301–305; discussion 305–306.
8.Anderson CD, Pinson CW, Berlin J, Chari RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004, 9(1):43–57.
9.Yang J, Yan LN: Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol 2008, 14(41):6289–6297.
10.Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ: Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014, 60(6):1268–1289.
11.Konstantinidis IT, Arkadopoulos N, Ferrone CR: Surgical management of intrahepatic cholangiocarcinoma in the modern era: advances and challenges. Chin Clin Oncol 2016, 5(1):9.
12.Shinohara ET, Mitra N, Guo M, Metz JM: Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008, 72(5):1495–1501.
13.Zheng X, Chen B, Wu JX, Jia AY, Rong WQ, Wang LM, Wu F, Zhao YT, Li YX, Wang WH: Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels. Cancer Manag Res 2018, 10:3973–3981.
14.Jiang W, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, Zhang JY, Chen YX, Tan YS: Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases. J Cancer Res Clin Oncol 2010, 136(9):1323–1331.
15.Horgan AM, Amir E, Walter T, Knox JJ: Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012, 30(16):1934–1940.
16.Hammad AY, Berger NG, Eastwood D, Tsai S, Turaga KK, Christian KK, Johnston FM, Pawlik TM, Gamblin TC: Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival. Ann Surg Oncol 2016, 23(Suppl 5):912–920.
17.Farges O, Fuks D, Le Treut YP, Azoulay D, Laurent A, Bachellier P, Nuzzo G, Belghiti J, Pruvot FR, Regimbeau JM: AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC–2009 study group. Cancer 2011, 117(10):2170–2177.
18.Song S, Kim K, Chie EK, Kim S, Park HJ, Yi NJ, Suh KS, Ha SW: Locoregional recurrence after curative intent resection for intrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy. Clin Transl Oncol 2015, 17(10):825–829.
19.Luvira V, Eurboonyanun C, Bhudhisawasdi V, Pugkhem A, Pairojkul C, Luvira V, Sathitkarnmanee E, Somsap K, Kamsa-ard S: Patterns of Recurrence after Resection of Mass-Forming Type Intrahepatic Cholangiocarcinomas. Asian Pac J Cancer Prev 2016, 17(10):4735–4739.
20.Gil E, Joh JW, Park HC, Yu JI, Jung SH, Kim JM: Predictors and patterns of recurrence after curative liver resection in intrahepatic cholangiocarcinoma, for application of postoperative radiotherapy: a retrospective study. World J Surg Oncol 2015, 13:227.
21.Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Clary BM, Aldrighetti L et al: Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 2013, 153(6):811–818.
22.Doussot A, Gonen M, Wiggers JK, Groot-Koerkamp B, DeMatteo RP, Fuks D, Allen PJ, Farges O, Kingham TP, Regimbeau JM et al: Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. J Am Coll Surg 2016, 223(3):493–505 e492.
23.Chen YX, Zeng ZC, Tang ZY, Fan J, Zhou J, Jiang W, Zeng MS, Tan YS: Prediction of the lymph node status in patients with intrahepatic cholangiocarcinoma: analysis of 320 surgical cases. Front Oncol 2011, 1:42.
24.Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM et al: Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 2015, 22(11):3716–3723.
25.Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, Boudjema K, Fartoux L, Bouhier-Leporrier K, Jouve JL et al: Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. J Clin Oncol 2019, 37(8):658–667.
26.Schweitzer N, Weber T, Kirstein MM, Fischer M, Kratzel AM, Reineke-Plaass T, Lehner F, Manns MP, Vogel A: The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis. J Cancer Res Clin Oncol 2017, 143(7):1347–1355.
27.Reames BN, Bagante F, Ejaz A, Spolverato G, Ruzzenente A, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK et al: Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. HPB (Oxford) 2017, 19(10):901–909.
28.Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M et al: Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019, 20(5):663–673.
29.Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, Wan X, Liu G, Wu D, Shi L et al: Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 2013, 31(9):1188–1195.
30.Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM, Aldrighetti L, Calise F, Gerunda GE, Tomatis M et al: Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients. Arch Surg 2012, 147(12):1107–1113.
31.Farges O, Fuks D, Boleslawski E, Le Treut YP, Castaing D, Laurent A, Ducerf C, Rivoire M, Bachellier P, Chiche L et al: Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC–2009 study group. Ann Surg 2011, 254(5):824–829; discussion 830.
32.de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Clary BM, Aldrighetti L et al: Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011, 29(23):3140–3145.
33.Jiang W, Zeng ZC, Tang ZY, Fan J, Sun HC, Zhou J, Zeng MS, Zhang BH, Ji Y, Chen YX: A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol 2011, 22(7):1644–1652.
34.Zhang GW, Lin JH, Qian JP, Zhou J: Identification of risk and prognostic factors for patients with clonorchiasis-associated intrahepatic cholangiocarcinoma. Ann Surg Oncol 2014, 21(11):3628–3637.
35.Zhou HB, Wang H, Li YQ, Li SX, Wang H, Zhou DX, Tu QQ, Wang Q, Zou SS, Wu MC et al: Hepatitis B virus infection: a favorable prognostic factor for intrahepatic cholangiocarcinoma after resection. World J Gastroenterol 2011, 17(10):1292–1303.
36.Yi B, Zhang BH, Zhang YJ, Jiang XQ, Zhang BH, Yu WL, Chen QB, Wu MC: Surgical procedure and prognosis of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2004, 3(3):453–457.
37.Yi B, Zhang BH, Zhang YJ, Jiang XQ, Zhang BH, Yu WL, Cheng QB, Wu MC: [Analysis of the relation between surgery and prognosis of hilar cholangiocarcinoma]. Zhonghua Wai Ke Za Zhi 2005, 43(13):842–845.
38.Kim HJ, Kang TU, Swan H, Kang MJ, Kim N, Ahn HS, Park SM: Incidence and Prognosis of Subsequent Cholangiocarcinoma in Patients with Hepatic Resection for Bile Duct Stones. Dig Dis Sci 2018, 63(12):3465–3473.
39.Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM: Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg 2014, 149(6):565–574.
40.Kato A, Naitoh I, Miyabe K, Hayashi K, Yoshida M, Hori Y, Natsume M, Jinno N, Asano G, Kato H et al: An Increased Chromosome 7 Copy Number in Endoscopic Bile Duct Biopsy Specimens Is Predictive of a Poor Prognosis in Cholangiocarcinoma. Dig Dis Sci 2018, 63(12):3376–3381.
41.Yamada T, Nakanishi Y, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, Tanaka K, Kurashima Y, Ebihara Y et al: Impact of serum carbohydrate antigen 19–9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma. J Gastroenterol Hepatol 2018.